The Serum Institute of India has informed the Centre that it will supply approximately 22 crore doses of Covishield in October, as the Union government has announced that surplus Covid vaccines will be exported again in the fourth quarter under the ‘Vaccine Maitri’ programme, according to official sources.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), stated in a communication to the Centre that the company has increased its Covishield production capacity, He said they would supply 21.90 crore doses to the Government of India and private hospitals in October. Singh further stated that the business would finish the latest supply order of 66 crore doses by December 31, by the timetable.
He stated that they would supply 66 crore doses of Covishield against the existing order by December 31, 2021, and that they will hit shipments of more than 130 crore doses of Covishield in 2021. They are working tirelessly to realise the prime minister’s objective of successfully completing the world’s largest vaccination programme in order for our country to fight the Covid-19 epidemic.
The Pune-based pharmaceutical business has increased Covishield’s production capacity to more than 20 crore pills per month. On Monday, Union Health Minister Mansukh Mandaviya announced that India will resume exporting surplus Covid-19 vaccines under the ‘Vaccine Maitri’ programme in the fourth quarter of 2021 and meet its commitment to the COVAX global pool but vaccinating its citizens remains the government’s top priority.